© 2005 Oxford University Press
NEWS |
Central IRBs: Why Are Some Institutions Reluctant To Sign On?
| The first 10% of the full text of this article appears below. |
There are several good reasons why hospitals and cancer centers would want to use central institutional review boards (IRBs) to supplement their often overburdened local boards that are charged with overseeing research involving human subjects. What's more, several national agencies support central IRBs: The U.S. Food and Drug Administration issued a draft guidance in March to help increase awareness of central IRBs, the Office for Human Research Protections (OHRP) looks favorably on them, and the American Society of Clinical Oncology officially endorses their use. So does the National Cancer Institute, which has established two central IRBs for institutions participating in its phase III cooperative group trials.
Centralized review, according to representatives from all of these organizations, can be more efficient and more effective in protecting clinical
Increase in Trials
Barriers to Use